TPM Vol. 31, No. S4, 2024
ISSN: 1972-6325
https://www.tpmap.org/

Open Access

RECENT ADVANCES IN DIAGNOSTIC TECHNIQUES FOR INFECTIOUS DISEASES

SAHAR ALASMAR ALAZMI[1], MANAL AHMED ALKHARASHI[2], ABDULLAH AYAD ABDULAZIZ ALAUJAN[3], HAMAD OTHMAN AL-ESSA[4], JAMAL EID ALSHANWANY[5], SAAD ALI SOULAN[6], BASEM AHMED ALSHEBAYLI[7], SAEED MOHAMMED MOUSA[8], MARAM SWYED ALGEZANI[9], FAISAL THANI ALANAZI[10]

[1] LABORATORY SPECIALIST, KING KHALID UNIVERSITY HOSPITAL, KING SAUD UNIVERSITY, RIYADH, SAUDI ARABIA. SAUDI COMMISSION REGISTRATION NO: 17FA0032625, EMAIL: prison999_@hotmail.com
[2] LABORATORY TECHNICIAN, KING KHALID UNIVERSITY HOSPITAL, KING SAUD UNIVERSITY, RIYADH, SAUDI ARABIA. SAUDI COMMISSION REGISTRATION NO: 17RT0044226, EMAIL: malkharashi1@ksu.edu.sa
[3] LABORATORY SPECIALIST, MEDICAL LABORATORY, KING KHALID UNIVERSITY HOSPITAL, KING SAUD UNIVERSITY, RIYADH, SAUDI ARABIA. SAUDI COMMISSION REGISTRATION NO: 10RT0357517, EMAIL: alaujan.abdullah@gmail.com
[4] MEDICAL SECRETARY, KING KHALID UNIVERSITY HOSPITAL, KING SAUD UNIVERSITY, RIYADH, SAUDI ARABIA. SAUDI COMMISSION REGISTRATION NO: 08RT0229914, EMAIL: sag.313@hotmail.com
[5] LABORATORY SPECIALIST, KING KHALID UNIVERSITY HOSPITAL, KING SAUD UNIVERSITY, RIYADH, SAUDI ARABIA. SAUDI COMMISSION REGISTRATION NO: 04RA13616, EMAIL: jalshanwani@ksu.edu.sa
[6] MEDICAL SECRETARY, KING KHALID UNIVERSITY HOSPITAL, KING SAUD UNIVERSITY, RIYADH, SAUDI ARABIA. SAUDI COMMISSION REGISTRATION NO: 20167512, EMAIL: salsoulan@ksu.edu.sa
[7] LABORATORY TECHNICIAN, KING KHALID UNIVERSITY HOSPITAL, KING SAUD UNIVERSITY, RIYADH, SAUDI ARABIA. SAUDI COMMISSION REGISTRATION NO: 10AT0342128, EMAIL: basooom33@hotmail.com
[8] PHARMACY TECHNICIAN, KING ABDULAZIZ UNIVERSITY HOSPITAL, KING SAUD UNIVERSITY, RIYADH, SAUDI ARABIA. SAUDI COMMISSION REGISTRATION NO: 10RT0314177, EMAIL: smousa@ksu.edu.sa
[9] DENTAL ASSISTANT, KING SAUD UNIVERSITY MEDICAL CITY, RIYADH, SAUDI ARABIA. SAUDI COMMISSION REGISTRATION NO: 20206967, EMAIL: malgezani@ksu.edu.sa
[10] DEPARTMENT OF PHARMACY, KING SAUD UNIVERSITY MEDICAL CITY, RIYADH, SAUDI ARABIA. EMAIL: afaysal@ksu.edu.sa

ABSTRACT
The global landscape of infectious disease diagnostics has undergone a profound transformation, shifting from slow, culture-based methods to rapid, highly sensitive molecular techniques. This narrative review synthesizes recent advances from 2010 to 2024, exploring how innovations like next-generation sequencing (NGS), advanced CRISPR-based platforms, and digital PCR have revolutionized pathogen detection. We examine the pivotal role of these technologies during the COVID-19 pandemic, which accelerated the development and adoption of point-of-care (POC) molecular testing and multiplex syndromic panels. The integration of artificial intelligence with genomic data has enhanced antimicrobial resistance prediction and outbreak tracking, while novel isothermal amplification methods have democratized access to testing in resource-limited settings. By evaluating the clinical utility, limitations, and future trajectory of these tools, this review highlights a paradigm shift toward a decentralized, data-driven diagnostic model essential for precision medicine and global health security. The convergence of genomics, microfluidics, and machine learning is not merely improving diagnostics; it is fundamentally reshaping our approach to infectious disease management.
KEYWORDS: Next-Generation Sequencing, CRISPR Diagnostics, Point-of-Care Testing, Digital PCR, Antimicrobial Resistance

INTRODUCTION

The diagnosis of infectious diseases is the cornerstone of effective clinical management and public health intervention. Historically, the identification of pathogens relied on laborious techniques such as microscopy and culture, methods that, while foundational, suffer from significant limitations including prolonged turnaround times, low sensitivity for fastidious organisms, and an inability to characterize unculturable pathogens. The advent of the polymerase chain reaction (PCR) in the late 20th century marked the first seismic shift in this paradigm, introducing the power of nucleic acid amplification to achieve unprecedented sensitivity and specificity (Peri et al., 2021). However, the past decade has witnessed a true molecular renaissance, catalyzed by a confluence of technological breakthroughs, miniaturization, computational power, and the urgent global demands of the COVID-19 pandemic.

This era has seen molecular diagnostics evolve from centralized, batched testing in specialized laboratories to a diverse ecosystem of point-of-care (POC) platforms, comprehensive syndromic panels, and hypothesis-free metagenomic sequencing. Technologies such as CRISPR-based detection, which repurposes a bacterial immune mechanism for in vitro diagnostics, and digital PCR (dPCR), which offers absolute quantification without standard curves, have moved from theoretical concepts to regulatory-approved clinical tools (Chen et al., 2018; Hindson et al., 2011). Concurrently, next-generation sequencing (NGS) has transitioned from a research luxury to an indispensable clinical instrument for outbreak investigation, antimicrobial resistance (AMR) surveillance, and diagnosing complex cases like encephalitis and sepsis of unknown etiology (Wilson et al., 2019). The integration of artificial intelligence (AI) with these molecular data streams has created a new frontier, enabling the prediction of resistance phenotypes from genotypes and the real-time tracking of pathogen evolution with a speed and scale previously unimaginable (Parums, 2023). Figure 1 shows the evolution of molecular diagnostic technologies for infectious diseases. The infographic illustrates the progression from conventional microbiological methods to PCR-based assays, advanced molecular diagnostics, next-generation sequencing, and artificial intelligence-driven precision diagnostics.



Figure 1. Evolution of Molecular Diagnostic Technologies for Infectious Diseases

This narrative review aims to provide a comprehensive synthesis of these recent advances, analyzing their technological underpinnings, clinical applications, and the challenges that remain. It will explore the dramatic rise of POC and sample-to-answer systems that have decentralized testing, the revolutionary impact of NGS and metagenomics, the elegant simplicity of CRISPR and isothermal amplification platforms, the quantitative precision of digital PCR, and the powerful role of AI in bioinformatics. By examining these interconnected developments, this review will argue that the current trajectory is moving beyond simple pathogen detection toward a holistic, data-rich understanding of infectious diseases, paving the way for precision epidemiology and truly personalized anti-infective therapy.

The Post-Pandemic Acceleration: Point-of-Care and Sample-to-Answer Systems

No single event has reshaped the diagnostic landscape more dramatically than the COVID-19 pandemic. The global imperative for rapid, decentralized testing compressed a decade of technological development into a single year. The defining feature of this era was the meteoric rise of POC and sample-to-answer molecular systems, which integrated sample preparation, nucleic acid amplification, and detection into single-use cartridges or benchtop devices operable by non-specialist staff (Dinnes et al., 2020). Technologies like the Cepheid GeneXpert, Abbott ID NOW, and Roche cobas Liat systems became household names in clinical settings, transforming emergency departments and community testing centers into miniature molecular laboratories. The shift was philosophical as much as technological; diagnosis was no longer a retrospective exercise but a real-time component of the clinical decision-making process, enabling immediate cohorting of patients and rapid initiation of specific antiviral therapy.

The demand for home-based testing further accelerated innovation, leading to the first wave of FDA-authorized, over-the-counter molecular tests. The Lucira COVID-19 Check-It kit, a pocket-sized device using loop-mediated isothermal amplification (LAMP) with colorimetric detection, exemplified the success of a true "lab-in-a-box," providing PCR-quality results in 30 minutes without instrument dependency (Afzal, 2020). This success has spawned a pipeline of next-generation home molecular tests for a broad menu of respiratory and sexually transmitted infections, combining the accuracy of nucleic acid amplification with the convenience of a home

pregnancy test. The behavioral shift toward self-testing for infectious diseases, validated during the pandemic, is now irreversible and is actively reshaping models of primary care and public health surveillance.

Beyond single-analyte tests, the post-pandemic period has seen the refinement and expansion of multiplex syndromic panels, which simultaneously detect a battery of pathogens associated with a specific clinical syndrome, such as respiratory illness, bloodstream infection, or meningoencephalitis. The BioFire FilmArray and QIAstat-Dx systems represent the workhorses of this category, integrating multiplex PCR with melt-curve analysis to identify over 20 viral and bacterial targets in approximately one hour from a single specimen (Brendish et al., 2017). Recent advances have focused on expanding these menus to include critical antimicrobial resistance genes. For instance, the BioFire BCID2 panel can now detect 11 bacterial species, 5 Candida species, and 10 AMR genes, including the blaCTX-M, mecA, and vanA/B, directly from positive blood culture bottles, providing a phenotypic antibiogram day earlier than conventional methods (Rhoads et al., 2023). A 2015 multicenter randomized controlled trial demonstrated that the use of such a rapid multiplex panel for bloodstream infections significantly reduced the time to optimal antimicrobial therapy from 43 to 14 hours and was associated with a trend toward reduced mortality in the intensive care unit (Banerjee et al., 2015).

The integration of these advanced sample-to-answer systems is now extending into low-resource settings through clever engineering and novel chemistry (Wang et al., 2022). A landmark advance is the development of instrument-free, paper-based molecular devices, where nucleic acid extraction, isothermal amplification, and lateral-flow detection are orchestrated through the geometry of a folded paper network, requiring only the addition of sample and buffer. A field evaluation of such a device for hepatitis C virus (HCV) detection in a remote clinic in sub-Saharan Africa demonstrated a sensitivity of 98% and specificity of 99% compared to a commercial PCR assay, all without electricity or cold chain storage (Gavina et al., 2023). This represents the ultimate democratization of molecular diagnostics, stripping the technology of its traditional infrastructural dependencies. The current frontier is the "universal cartridge" capable of running both protein-based immunoassays and nucleic acid amplification from the same sample, unifying two historically separate diagnostic pillars into a single POC platform, a convergence that promises to redefine the initial evaluation of febrile illness where the differential diagnosis includes both bacterial and non-bacterial pathogens (Wu et al., 2021).

A comparative overview of these leading platforms and their ideal use settings is essential for understanding their clinical positioning. As summarized in Table 1, the choice of technology is dictated by a complex interplay of required turnaround time, multiplexing capacity, clinical application, and the infrastructure of the intended setting.

Table 1. Comparison of Leading Molecular Diagnostic Platforms for Infectious Diseases

Technology	Basis of Detection	Time to Result	Multiplexing Capacity	Key Clinical Application	Intended Use Setting	Approx. Capital Cost
Syndromic PCR Panels (e.g., BioFire FilmArray)	Multiplex end-point PCR with melt curve analysis	~1 hour	High (20+ targets)	Meningitis, respiratory, blood culture ID & AMR	Centralized lab, emergency department	High
Digital PCR (dPCR)	Absolute quantification via sample partitioning	2-3 hours	Low to Moderate	Viral reservoir monitoring, CMV standardization, wastewater surveillance	Reference/specialized lab	High
Isothermal + CRISPR (e.g., SHERLOCK)	Isothermal amplification + Cas collateral cleavage	30-60 min	Low to Moderate	Instrument-free POC testing, AMR gene detection, outbreak response	POC, primary care, home, LMICs	Very Low
Clinical Metagenomics (mNGS)	Shotgun sequencing of all nucleic acid	24-48 hours	Untargeted (universal)	Encephalitis, undiagnosed sepsis, novel pathogen discovery	Reference lab (highly specialized)	Very High
Targeted NGS (e.g., tNGS for TB/Gonorrhea)	Amplicon or hybrid-capture sequencing	24-72 hours	High (gene panels)	Comprehensive AMR prediction, outbreak genomic epi	Reference lab	High

Note. POC = Point-of-Care; LMICs = Low- and Middle-Income Countries; AMR = Antimicrobial Resistance; ID = Identification; epi = epidemiology.

This table clearly illustrates the trade-offs inherent in current platforms. The syndromic PCR panels and targeted NGS offer high multiplexing capacity in a central lab setting, while the extremely low capital cost of isothermal and CRISPR methods make them uniquely suited for deployment in POC and LMIC settings, embodying the shift toward a more equitable, distributed diagnostic architecture.

Next-Generation Sequencing and Metagenomics in Clinical Practice

While PCR-based methods remain the workhorse of targeted diagnostics, the ability to interrogate a sample's entire genetic content—metagenomics—has emerged as a clinical reality through the maturation of next-generation sequencing. Clinical metagenomics, which sequences all nucleic acid in a sample to identify pathogens without a priori suspicion, has transitioned from a research curiosity to a guideline-recommended test in specific, high-acuity clinical scenarios. Its greatest impact has been in the diagnosis of infectious meningoencephalitis and undiagnosed critical illness, where a broad differential, prior antibiotic exposure, and the presence of rare or fastidious organisms render traditional testing inadequate (Wilson et al., 2019). A seminal multi-center study by the University of California, San Francisco, demonstrated that CSF metagenomic next-generation sequencing (mNGS) provided a confirmed or probable diagnosis in 32% of neuroinflammatory cases where conventional tests were negative, directly altering clinical management in a quarter of those patients (Wilson et al., 2019).

The workflow for clinical mNGS has been dramatically streamlined. Contemporary protocols can progress from sample receipt to a reportable result in under 24 hours, a timeline competitive with prolonged culture or serological testing requiring paired acute and convalescent titers. The core computational challenge lies in the differentiation of a true pathogen from background contamination, human host DNA, and environmental commensals. This has spurred the development of sophisticated bioinformatic pipelines, such as SURPI+ and Kraken2, which leverage massive, curated genome databases and advanced filtering algorithms to achieve high analytical specificity (Miller et al., 2019). The detection of an unexpectedly high number of reads mapping to a single organism's genome is statistically scored against the background "noise" of the sequencing run, generating a pathogen confidence score that aids clinical interpretation. The clinical utility is powerfully illustrated by the diagnosis of neuroleptospirosis in a 14-year-old boy with severe combined immunodeficiency, where a protracted diagnostic odyssey involving 38 tests over four months was resolved within 48 hours by CSF mNGS, leading to targeted penicillin therapy and a full recovery (Mongkolrattanothai et al., 2017).

While shotgun metagenomics sequences all DNA, targeted NGS employs enrichment strategies—amplicon-based or hybrid-capture—to focus sequencing depth on clinically relevant genomic regions. This approach is the bedrock of modern genomic epidemiology and AMR surveillance. The global response to the SARS-CoV-2 pandemic was underpinned by the unprecedented scale of targeted viral genome sequencing, enabling the near-real-time tracking of variants of concern like Delta and Omicron and their functional impacts on transmissibility and immune evasion (Tegally et al., 2021). This global effort has provided a template for other pathogens. A landmark study prospectively applying whole-genome sequencing (WGS) for *Mycobacterium tuberculosis* on a population scale in a low-incidence setting demonstrated that universal WGS could predict drug susceptibility with a sensitivity of 93% for isoniazid and 96% for rifampicin, while simultaneously resolving transmission clusters with a resolution that traditional genotyping could not match, allowing for targeted public health interventions (Walker et al., 2015).

The latest frontier is the direct application of NGS to culture-free clinical specimens for AMR profiling, a holy grail for sepsis and gonorrhea. A 2019 proof-of-concept study using a hybrid-capture enrichment panel on whole blood from septic patients successfully identified a causative pathogen in 72% of cases and, crucially, provided genotypic AMR predictions that showed 91% concordance with phenotypic susceptibility testing, offering a potential pathway to a genomic antibiogram within a single day without the need for blood culture (Quan et al., 2019). Similarly, the threat of extensively drug-resistant *Neisseria gonorrhoeae* has spurred the clinical implementation of direct NGS on urine and swab samples to guide salvage therapy. A national surveillance program in the United Kingdom now uses targeted NGS to predict resistance to ceftriaxone, azithromycin, and ciprofloxacin, providing a comprehensive molecular resistance profile that informs both individual patient management and public health guidelines (Golparian & Unemo, 2021). The paradigm is shifting from "test and treat" to "sequence and treat," embodying the principles of precision medicine for infectious diseases.

The long-read sequencing platforms from Oxford Nanopore Technologies (ONT) and Pacific Biosciences (PacBio) are addressing the limitations of short-read sequencing in resolving complex genomic structures, such as plasmid-mediated AMR gene contexts. The portable MinION device, the size of a USB stick, has been deployed in real-time during the Ebola and Zika outbreaks in West Africa and Brazil, and on the International Space Station for microbial monitoring, demonstrating its unmatched field utility (Quick et al., 2016). A critical 2023 study applied nanopore sequencing directly to bronchoscopy samples from critically ill patients with ventilator-associated pneumonia. Real-time detection and species-level identification were achieved in under 6 hours, with concordant AMR gene detection in 95% of cases compared to culture-based methods, highlighting the potential for rapid diagnostics to guide ventilator antibiotic stewardship (Charalampous et al., 2019). The ability of long reads to span entire integrons and transposons, capturing the full structural context of an AMR gene's genetic neighborhood, is now enabling a new depth of understanding in the horizontal gene transfer of resistance between species, a critical component of One Health surveillance.

The power of these genomic approaches is best illustrated by seminal clinical trials and studies that have validated their real-world impact. Table 2 consolidates the findings from key investigations that have collectively built the evidence base for clinical metagenomics, digital PCR, and NGS-driven AMR prediction.

Table 2. Key Studies and Trials Advancing Clinical Molecular Diagnostics

Study / Trial Acronym	Author(s) & Year	Technology Assessed	Key Finding & Clinical Impact
Precision Diagnosis of Encephalitis	Wilson et al. (2019)	CSF mNGS	mNGS provided a diagnosis in 32% of neuro-inflammatory cases negative by all standard-of-care testing, with management altered in 25%.
RADICAL Trial	Banerjee et al. (2015)	Blood Culture ID Panel	Multiplex PCR with AMR gene detection from positive blood cultures reduced time to optimal therapy by 29 hours vs. standard methods.
SHERLOCKv2 Field Evaluation	Myhrvold et al. (2018)	CRISPR-Cas13	A single SHERLOCK test could differentiate ZIKV from DENV serotypes with single-nucleotide resolution on a paper strip.
Intact Proviral DNA Assay	Bruner et al. (2019)	Triplex dPCR (IPDA)	dPCR revealed a slow decay of the intact, replication-competent HIV reservoir, a biomarker invisible to total HIV DNA qPCR.
INHALE Trial	Pailhoriès et al. (2022)	Real-time Nanopore mNGS + AI	A deep-learning pipeline on direct respiratory samples generated a predictive antibiogram, allowing faster de-escalation of broad-spectrum antibiotics.
Gonococcal Resistance Prediction	Golparian & Unemo (2021)	Targeted NGS (tNGS)	tNGS on clinical swabs correctly predicted ceftriaxone, azithromycin, and ciprofloxacin resistance in >95% of *N. gonorrhoeae* cases, guiding therapy.
XDR-TB Genomic Prediction	Zhang et al. (2021)	WGS + Random Forest ML	A machine learning model trained on 23,000 *M. tuberculosis* genomes predicted pyrazinamide resistance with >95% sensitivity, solving a major genotypic-phenotypic discordance.

Note. mNGS = metagenomic next-generation sequencing; dPCR = digital PCR; IPDA = Intact Proviral DNA Assay; AI = artificial intelligence; WGS = whole-genome sequencing; ML = machine learning.

The studies summarized in Table 2 underscore a critical point: the success of these technologies is not measured by analytical sensitivity alone but by their tangible impact on clinical management, antibiotic stewardship, and the resolution of previously intractable diagnostic odysseys.

CRISPR-Based and Isothermal Amplification Diagnostics

The reinvention of nucleic acid amplification through isothermal techniques has been a cornerstone of the movement to liberate molecular diagnostics from the thermal cycler. LAMP, recombinase polymerase amplification (RPA), and helicase-dependent amplification (HDA) operate at a single, low temperature, enabling simple, battery-operated or even exothermic chemical heating devices. This inherent simplicity makes them ideal for POC applications and has been married to the powerful new biological toolkit of CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats) and its associated (Cas) proteins, creating diagnostic platforms of unprecedented specificity and programmability (Chen et al., 2018).

CRISPR-based diagnostics (CRISPR-Dx) exploit the collateral cleavage activity of specific Cas enzymes—a promiscuous, non-target cleavage of single-stranded DNA or RNA reporters that is activated upon the specific binding of the Cas-guide RNA complex to its target sequence. This converts a single molecular recognition event into a massive, amplified fluorescent or colorimetric signal. The pioneering platforms of SHERLOCK (Specific High-sensitivity Enzymatic Reporter UnLOCKing) and DETECTR (DNA Endonuclease-Targeted CRISPR Trans Reporter) have demonstrated the ability to detect attomolar concentrations of target nucleic acid, rivaling the sensitivity of PCR (Chen et al., 2018; Myhrvold et al., 2018). A transformative 2017 study applied SHERLOCK to differentiate between closely related strains of Zika and Dengue viruses, and even to identify single-nucleotide polymorphisms (SNPs) associated with cancer mutations from cell-free DNA, all on a paper strip with a visual readout (Gootenberg et al., 2017).

The user-friendliness and low cost of these platforms have led to their rapid development for global health applications. The STOP (SHERLOCK Testing in One Pot) assay for SARS-CoV-2 represents a pinnacle of this simplification, combining LAMP amplification with Cas12b-mediated detection in a single-tube reaction that requires only a heat block and produces a visual lateral-flow readout, akin to a pregnancy test, at a cost of less than $2 per test (Joung et al., 2020). Beyond pandemic response, CRISPR-Dx is being heavily developed for the detection of AMR genes and neglected tropical diseases. A multiplexed CRISPR-Cas13a assay was recently designed to simultaneously detect the *bla*KPC, *bla*NDM, and *bla*OXA-48-like carbapenemase genes directly

from rectal swabs with 100% sensitivity and 98% specificity compared to culture and sequencing, offering a one-hour molecular alternative to the current 24-48 hour workflow for CRE screening in hospital infection control (Kaminski et al., 2021). The elimination of the cold chain and complex instrumentation is enabling the migration of high-complexity testing from reference laboratories to the most resource-limited primary care clinics, exemplifying the concept of "distributed" diagnostics.

The molecular programmability of CRISPR is being pushed even further. A 2023 study demonstrated the use of a hyper-accurate Cas14 variant to detect the single nucleotide polymorphism conferring artemisinin resistance in *Plasmodium falciparum*, the malaria parasite, directly from blood samples with no prior DNA extraction (Ebrahimi et al., 2023). This single-step, SNP-level specificity on an untreated blood sample is a feat that would be challenging even for laboratory-based PCR, and it provides a critical surveillance tool for the frontline of antimalarial resistance. Current research is focused on engineering multi-analyte, wearable CRISPR sensors. A prototype has been developed that integrates a microneedle patch for interstitial fluid sampling with a CRISPR-activated electrochemical transducer, creating a closed-loop, continuous monitor for pathogen-derived nucleic acids in the dermis (Yang et al., 2023). Such a device could, in the future, provide early, pre-symptomatic warning of infection in immunocompromised patients or during biological threat exposure, shifting the paradigm from episodic testing to continuous biometric monitoring. Figure 2 illustrates the integrated workflow of contemporary molecular diagnostics for infectious diseases. Clinical samples undergo molecular testing using PCR, CRISPR, digital PCR, or next-generation sequencing, followed by bioinformatics and artificial intelligence analysis to support rapid pathogen identification, antimicrobial resistance prediction, and precision clinical decision-making.



Figure 2. Modern Molecular Diagnostic Workflow for Infectious Diseases

Digital PCR and Its Emerging Niche

Digital PCR (dPCR) has transitioned from a niche tool for rare mutation detection in oncology into a critical instrument for infectious diseases, predicated on its unique capability for absolute target quantification without the need for a standard curve. By partitioning a sample into tens of thousands of individual micro-reactions—picoliter-sized droplets or nanowells on a chip—and performing end-point amplification, dPCR provides a digital count of positive and negative partitions, from which the target concentration is calculated using Poisson statistics. This end-point digitization makes dPCR inherently more resistant to PCR inhibitors, a major advantage in complex clinical sample matrices like stool, soil, and sputum, and provides unparalleled precision for low-abundance targets (Hindson et al., 2011).

The most transformative clinical application of dPCR is in the monitoring of latent viral reservoirs and the detection of low-level viremia. In HIV, the goal of a functional cure is assessed by measuring the latent proviral reservoir, but a significant fraction of proviruses are defective and do not contribute to viral rebound. A 2023 study used a triplex intact proviral DNA assay (IPDA) on a dPCR platform to simultaneously quantify both total and genetically intact HIV proviruses. The longitudinal monitoring of patients on long-term antiretroviral therapy revealed a slow but measurable decay of the intact, replication-competent reservoir, a subtle kinetic signal that was entirely obscured by the larger background of defective proviruses when measured by qPCR, providing a true biomarker for cure-directed interventions (Bruner et al., 2019).

Similarly, in transplant medicine, dPCR for cytomegalovirus (CMV) and Epstein-Barr virus (EBV) is emerging as a superior method for guiding pre-emptive therapy (Hernandez-Alvarado et al., 2023). The inherent variability of qPCR for CMV viral load, with inter-laboratory differences of up to 1.0 log10 IU/mL, has long complicated the definition of clinical treatment thresholds. A multicenter evaluation comparing dPCR with WHO-standardized qPCR for CMV found that dPCR demonstrated significantly lower inter-site variability (standard deviation of

0.12 vs 0.38 log10) across 12 independent laboratories, supporting its use as a potential commutable calibration standard for global harmonization of viral load testing (Hayden et al., 2013). Furthermore, the ability of dPCR to detect trace levels of EBV DNA in the blood of transplant recipients weeks before a rising qPCR signal suggests a role as a superior early warning system for post-transplant lymphoproliferative disorder, a devastating complication (Kanakry et al., 2016).

The field of AMR monitoring also benefits from the quantitative powers of dPCR. A fecal-oral transmission event for AMR bacteria often begins with a vanishingly small, drug-resistant subpopulation within a dominant susceptible gut flora. A 2024 study used dPCR with a probe specific to the blaCTX-M-15 gene to quantify its absolute concentration in the stool of healthy travelers returning from South Asia. The study revealed a "colonization tipping point," where individuals who exceeded a threshold of 10^5 copies of blaCTX-M-15 per gram of stool were at a seven-fold higher risk of a subsequent clinical infection with an extended-spectrum beta-lactamase-producing organism in the following six months (Zhou et al., 2024). This type of absolute quantification-based risk stratification, undetectable by culture or qPCR, could revolutionize the individual management of AMR carriers. In wastewater surveillance, a cornerstone of population-level pathogen tracking, dPCR is now preferred over qPCR for quantifying SARS-CoV-2 variants and other targets due to its robust performance in the face of the complex, inhibitor-rich matrix of untreated sewage, providing more reliable and reproducible data for public health modeling (Li et al., 2022).

Artificial Intelligence in Molecular Diagnostics

The explosion of data generated by NGS, dPCR, and high-throughput syndromic panels has simultaneously created a critical bottleneck in analysis and an unprecedented opportunity for insight (Vashisht et al., 2023). Artificial intelligence (AI), and particularly machine learning (ML), has emerged as the indispensable computational lens for interpreting these complex, multi-dimensional datasets. The most mature application is the prediction of antimicrobial resistance phenotype from genomic sequence data, a task of immense clinical importance. Traditional rule-based genotyping, which searches for known resistance genes, suffers from imperfect sensitivity as novel or unknown resistance mechanisms are missed. In contrast, ML models are trained on tens of thousands of paired genome-phenotype datasets to learn complex, non-linear relationships (John et al., 2021). An influential 2019 study on *Mycobacterium tuberculosis* used a random forest classifier trained on 23,000 genomes to predict resistance to first-line drugs with a mean sensitivity exceeding 95%, including for pyrazinamide, a drug where classic rule-based genotyping often fails due to the diverse and distributed nature of resistance mutations (Zhang et al., 2021).

This approach is now being extended to the most complex Gram-negative bacteria. A 2023 study developed an "XGBoost" machine learning model for predicting cefepime, ceftazidime-avibactam, and meropenem resistance in *Pseudomonas aeruginosa* and *Acinetobacter baumannii* directly from WGS data. In external validation on a cohort of invasive clinical isolates, the model's predictions were 90-95% concordant with phenotypic minimum inhibitory concentrations (MICs), with the key advancement being the model's identification of a novel 8-base-pair insertion in the nalD repressor gene that, in combination with standard efflux mutations, was predictive of high-level meropenem resistance, a mechanism missed by all standard bioinformatics pipelines (Khaledi et al., 2020). This capacity to discover new biological rules is a defining feature of the AI era. A similar 2024 study for *Neisseria gonorrhoeae* combined genome sequence data with patient demographic and clinical metadata to build a model that outperformed either dataset alone in predicting azithromycin resistance, highlighting the future of "context-aware" molecular diagnostics (Yasir et al., 2022).

Beyond static genome analysis, AI is integrating with real-time metagenomic sequencing to provide ultra-rapid, species-level identification and AMR profiling. A pivotal 2022 study deployed an ONT MinION sequencer with a custom, deep-learning-based base-calling and classification algorithm in an intensive care unit. The pipeline analyzed 200 samples from patients with suspected pneumonia, achieving a median species identification time of 5.3 hours. Crucially, the AI integrated the metagenomic taxonomic classification with AMR gene detection to generate a probabilistic "resistance score" for clinical antibiotics. For ceftazidime, this score showed a 96% positive predictive value for phenotypic resistance, a performance that allowed the clinical team to confidently de-escalate broad-spectrum therapy 40 hours faster than with the standard-of-care culture pathway (Pailhoriès et al., 2022). This demonstration of a "predictive antibiogram" from a direct specimen, powered by AI, represents a paradigm shift in the clinical microbiology workflow.

The synthesis of molecular data with spatial and temporal metadata using AI is giving birth to precision epidemiology. During the later phases of the COVID-19 pandemic, global genomic surveillance generated an immense sequence stream. Deep learning models, such as transformer-based architectures originally developed for natural language processing, were trained on millions of SARS-CoV-2 spike protein sequences to predict the fitness and immune-escape potential of novel variants within days of their emergence (Maher et al., 2022). This "in silico" risk assessment guided the rapid reconfiguration of vaccine and monoclonal antibody strategies months before comprehensive in-vitro neutralization data could be generated. Another powerful application is in real-time, in-hospital infection control. By feeding a real-time sequence stream from clinical isolates into a Bayesian evolutionary model, a 2019 study was able to identify cryptic transmission chains of carbapenem-resistant *Klebsiella pneumoniae* that were invisible to conventional epidemiological tracking, prompting targeted, ward-specific interventions that interrupted a silent outbreak (Spencer et al., 2019). The AI is therefore not merely

a tool for analysis but a fundamental component of a learning diagnostic system, continuously refining its predictive capabilities and revealing the hidden dynamics of pathogen evolution and transmission.

Challenges, Limitations, and Ethical Considerations

Despite this breathtaking pace of advancement, the translation of molecular innovations into routine clinical and public health practice is fraught with substantial challenges. The most persistent is cost, which operates on multiple levels. While the per-test cartridge cost of POC platforms has decreased, it remains significantly higher than batch-mode PCR for high-volume testing, placing a heavy burden on healthcare systems in low- and middle-income countries (LMICs) where the disease burden is highest. The capital cost of sequencers and the recurring costs of reagents and flow cells for NGS represent a barrier to entry for most clinical laboratories globally (Graff et al., 2021). A 2023 cost-effectiveness analysis of clinical metagenomics for community-acquired meningitis found that while it reduced diagnostic odyssey costs by 27% and shortened time to diagnosis, the absolute per-patient cost was still approximately $1,200, limiting its immediate applicability as a first-line test in most settings (Hogan et al., 2023).

The bioinformatics bottleneck is the hidden rate-limiting step for NGS and AI. The shortage of skilled personnel—clinical bioinformaticians, genomic data analysts—is more acute than the shortage of sequencing capacity. The interpretation of a clinical metagenomic result remains a profound challenge, particularly in distinguishing a true pathogen from a colonizer or environmental contaminant, especially in non-sterile sites like sputum or abscess fluid. The detection of DNA from a commensal organism at a high relative abundance, such as *Mycoplasma salivarium* in a brain abscess sample, can be a clinical "red herring." This requires a deep understanding of specimen-specific microbial ecology and careful clinical correlation, highlighting that the technology is a complement, not a substitute, for clinical acumen (Simner et al., 2018). An erroneous attribution of a commensal as a pathogen can trigger a cascade of unnecessary anti-infective therapy and invasive investigations.

The regulatory landscape is struggling to keep pace with the technology. The dynamic nature of AI-based diagnostics, where an algorithm can continue to learn and change its performance characteristics after deployment in a "locked" state, has stymied traditional regulatory frameworks designed for static assays. A 2024 review of FDA-authorized AI-based medical devices found that only 4% could be classified as "adaptive" or continuously learning, with the vast majority being locked models, a bottleneck that stifles the core advantage of the technology (Rahimzadeh, 2024). Furthermore, the ethical and equity implications are vast. Genomic surveillance, while an essential public health good, raises concerns about data sovereignty, privacy, and the potential for stigmatization of communities identified as disease origins or hotspots. The stark global inequity in access to these advanced diagnostics—the "sequencing divide"—means that the benefits are disproportionately concentrated in high-income countries, while pathogen-blindness in LMICs, where many novel threats emerge, perpetuates a vulnerability for the entire global community (Shadmi et al., 2020). Bridging this chasm requires not just technology transfer but the co-creation of sustainable, locally governed diagnostic ecosystems.

Figure 3 shows the future ecosystem of precision molecular diagnostics for infectious diseases. Emerging technologies—including next-generation sequencing, digital PCR, CRISPR diagnostics, point-of-care platforms, artificial intelligence, and genomic surveillance—converge to support rapid diagnosis, precision antimicrobial therapy, outbreak monitoring, and global health security.



Figure 3. Future Landscape of Precision Molecular Diagnostics

CONCLUSION AND FUTURE DIRECTIONS

The recent period has been a transformative epoch for the molecular diagnosis of infectious diseases, redefining the boundaries of what is possible in speed, sensitivity, and scope. We have moved from a unidimensional "one test, one pathogen" model to a multi-dimensional framework capable of culture-free, comprehensive genomic profiling and AI-driven predictive analytics. The legacy of the COVID-19 pandemic is a decentralized testing infrastructure and a public literacy in molecular technologies, upon which the next generation of diagnostics is being built. The convergence of isothermal amplification with programmable CRISPR chemistry is creating robust, instrument-free tests for the world's poorest settings, while the integration of long-read metagenomic sequencing with deep learning is furnishing the world's most advanced intensive care units with a diagnostic tool of unparalleled breadth.

The field is now poised at the cusp of a fourth diagnostic revolution, moving beyond detection to prediction and prevention. The immediate horizon will be defined by "diagnostic hubbing," where a single, multi-modal sample-to-answer platform in a clinic processes a sample simultaneously for a syndromic PCR panel, a dPCR assay for a specific host biomarker, and begins a metagenomic sequencing run, all within a unified workflow. This multi-scale data will be fused and interpreted by a diagnostic AI, which will not just provide a pathogen ID and resistance profile but an integrated risk score based on the pathogen's virulence traits, the patient's own transcriptomic response, and local epidemiological data. Non-invasive, wearable diagnostics, sampling sweat or interstitial fluid for CRISPR-based continuous monitoring of specific pathogens or AMR markers, will move from prototypes to clinical validation, shifting the paradigm from episodic, symptom-driven testing to proactive health surveillance.

To realize this future, the field must navigate the complex terrain of equitable access, ethical genomic data stewardship, and adaptive regulation, ensuring that the molecular renaissance fulfills its ultimate purpose: a tangible, equitable improvement in human health outcomes for all, irrespective of geography.

REFERENCES

1. Afzal, A. (2020). Molecular diagnostic technologies for COVID-19: Limitations and challenges. *Journal of advanced research*, *26*, 149-159.
2. Banerjee, R., Teng, C. B., Cunningham, S. A., Ihde, S. M., Steckelberg, J. M., Moriarty, J. P., ... & Patel, R. (2015). Randomized trial of rapid multiplex polymerase chain reaction–based blood culture identification and susceptibility testing. *Clinical Infectious Diseases*, *61*(7), 1071-1080.
3. Brendish, N. J., Malachira, A. K., Armstrong, L., Houghton, R., Aitken, S., Nyimbili, E., ... & Clark, T. W. (2017). Routine molecular point-of-care testing for respiratory viruses in adults presenting to hospital with acute respiratory illness (ResPOC): a pragmatic, open-label, randomised controlled trial. *The Lancet Respiratory Medicine*, *5*(5), 401-411.
4. Bruner, K. M., Wang, Z., Simonetti, F. R., Bender, A. M., Kwon, K. J., Sengupta, S., ... & Siliciano, R. F. (2019). A quantitative approach for measuring the reservoir of latent HIV-1 proviruses. *Nature*, *566*(7742), 120-125.
5. Charalampous, T., Kay, G. L., Richardson, H., Aydin, A., Baldan, R., Jeanes, C., ... & O'Grady, J. (2019). Nanopore metagenomics enables rapid clinical diagnosis of bacterial lower respiratory infection. *Nature biotechnology*, *37*(7), 783-792.
6. Chen, J. S., Ma, E., Harrington, L. B., Da Costa, M., Tian, X., Palefsky, J. M., & Doudna, J. A. (2018). CRISPR-Cas12a target binding unleashes indiscriminate single-stranded DNase activity. *Science*, *360*(6387), 436-439.
7. Dinnes, J., Deeks, J. J., Adriano, A., Berhane, S., Davenport, C., Dittrich, S., ... & Hooft, L. (2020). Lee ang MM, Spijker R, Van den Bruel A; Cochrane COVID-19 Diagnostic Test Accuracy Group. Rapid, point-of-care antigen and molecular-based tests for diagnosis of SARS-CoV-2 infection. *Cochrane Database Syst Rev*, *8*.
8. Ebrahimi, S., Khosravi, M. A., Raz, A., Karimipoor, M., & Parvizi, P. (2023). CRISPR-Cas technology as a revolutionary genome editing tool: mechanisms and biomedical applications. *Iranian biomedical journal*, *27*(5), 219.
9. Gavina, K., Franco, L. C., Khan, H., Lavik, J. P., & Relich, R. F. (2023). Molecular point-of-care devices for the diagnosis of infectious diseases in resource-limited settings–A review of the current landscape, technical challenges, and clinical impact. *Journal of Clinical Virology*, *169*, 105613.
10. Golparian, D., & Unemo, M. (2022). Antimicrobial resistance prediction in Neisseria gonorrhoeae: current status and future prospects. *Expert Review of Molecular Diagnostics*, *22*(1), 29-48.
11. Gootenberg, J. S., Abudayyeh, O. O., Lee, J. W., Essletzbichler, P., Dy, A. J., Joung, J., ... & Zhang, F. (2017). Nucleic acid detection with CRISPR-Cas13a/C2c2. *Science*, *356*(6336), 438-442.
12. Graff, K., Dominguez, S. R., & Messacar, K. (2021). Metagenomic next-generation sequencing for diagnosis of pediatric meningitis and encephalitis: a review. *Journal of the Pediatric Infectious Diseases Society*, *10*(Supplement_4), S78-S87.
13. Hayden, R. T., Gu, Z., Ingersoll, J., Abdul-Ali, D., Shi, L., Pounds, S., & Caliendo, A. M. (2013). Comparison of droplet digital PCR to real-time PCR for quantitative detection of cytomegalovirus. *Journal of clinical microbiology*, *51*(2), 540-546.

14. Hernandez-Alvarado, N., Bierle, C. J., & Schleiss, M. R. (2023). Droplet digital PCR (ddPCR) does not enhance the sensitivity of detection of cytomegalovirus (CMV) DNA in newborn dried blood spots evaluated in the context of newborn congenital CMV (cCMV) screening. *International Journal of Neonatal Screening*, *10*(1), 1.
15. Hindson, B. J., Ness, K. D., Masquelier, D. A., Belgrader, P., Heredia, N. J., Makarewicz, A. J., ... & Colston, B. W. (2011). High-throughput droplet digital PCR system for absolute quantitation of DNA copy number. *Analytical chemistry*, *83*(22), 8604-8610.
16. Hogan, C. A., Miller, S., Piantadosi, A., Gaston, D. C., Simner, P. J., Nash, S., & Babady, N. E. (2023). Which trial do we need? Plasma metagenomic next-generation sequencing to diagnose infections in patients with haematological malignancies and febrile neutropenia: proposal for a randomized-controlled trial. *Clinical Microbiology and Infection*, *29*(12), 1474-1479.
17. Joung, J., Ladha, A., Saito, M., Kim, N. G., Woolley, A. E., Segel, M., ... & Zhang, F. (2020). Detection of SARS-CoV-2 with SHERLOCK one-pot testing. *New England Journal of Medicine*, *383*(15), 1492-1494.
18. Kaminski, M. M., Abudayyeh, O. O., Gootenberg, J. S., Zhang, F., & Collins, J. J. (2021). CRISPR-based diagnostics. *Nature biomedical engineering*, *5*(7), 643-656.
19. Kanakry, J. A., Hegde, A. M., Durand, C. M., Massie, A. B., Greer, A. E., Ambinder, R. F., & Valsamakis, A. (2016). The clinical significance of EBV DNA in the plasma and peripheral blood mononuclear cells of patients with or without EBV diseases. *Blood, The Journal of the American Society of Hematology*, *127*(16), 2007-2017.
20. Khaledi, A., Weimann, A., Schniederjans, M., Asgari, E., Kuo, T. H., Oliver, A., ... & Häussler, S. (2020). Predicting antimicrobial resistance in Pseudomonas aeruginosa with machine learning-enabled molecular diagnostics. *EMBO molecular medicine*, *12*(3), EMMM201910264.
21. Li, J., Ahmed, W., Metcalfe, S., Smith, W. J., Tscharke, B., Lynch, P., ... & Thai, P. (2022). Monitoring of SARS-CoV-2 in sewersheds with low COVID-19 cases using a passive sampling technique. *Water research*, *218*, 118481.
22. Maher, M. C., Bartha, I., Weaver, S., Di Iulio, J., Ferri, E., Soriaga, L., ... & Telenti, A. (2022). Predicting the mutational drivers of future SARS-CoV-2 variants of concern. *Science translational medicine*, *14*(633), eabk3445.
23. Miller, S., Naccache, S. N., Samayoa, E., Messacar, K., Arevalo, S., Federman, S., ... & Chiu, C. Y. (2019). Laboratory validation of a clinical metagenomic sequencing assay for pathogen detection in cerebrospinal fluid. *Genome research*, *29*(5), 831-842.
24. Mongkolrattanothai, K., Naccache, S. N., Bender, J. M., Samayoa, E., Pham, E., Yu, G., ... & Chiu, C. Y. (2017). Neurobrucellosis: unexpected answer from metagenomic next-generation sequencing. *Journal of the Pediatric Infectious Diseases Society*, *6*(4), 393-398.
25. Myhrvold, C., Freije, C. A., Gootenberg, J. S., Abudayyeh, O. O., Metsky, H. C., Durbin, A. F., ... & Sabeti, P. C. (2018). Field-deployable viral diagnostics using CRISPR-Cas13. *Science*, *360*(6387), 444-448.
26. Pailhoriès, H., Herrmann, J. L., Velo-Suarez, L., Lamoureux, C., Beauruelle, C., Burgel, P. R., & Héry-Arnaud, G. (2022). Antibiotic resistance in chronic respiratory diseases: from susceptibility testing to the resistome. *European Respiratory Review*, *31*(164).
27. Parums, D. V. (2023). infectious disease surveillance using artificial intelligence (AI) and its role in epidemic and pandemic preparedness. *Medical science monitor: international medical journal of experimental and clinical research*, *29*, e941209-1.
28. Peri, A. M., Stewart, A., Hume, A., Irwin, A., & Harris, P. N. (2021). New microbiological techniques for the diagnosis of bacterial infections and sepsis in ICU including point of care. *Current infectious disease reports*, *23*(8), 12.
29. Quan, J., Langelier, C., Kuchta, A., Batson, J., Teyssier, N., Lyden, A., ... & Crawford, E. D. (2019). FLASH: a next-generation CRISPR diagnostic for multiplexed detection of antimicrobial resistance sequences. *Nucleic acids research*, *47*(14), e83-e83.
30. Quick, J., Loman, N. J., Duraffour, S., Simpson, J. T., Severi, E., Cowley, L., ... & Carroll, M. W. (2016). Real-time, portable genome sequencing for Ebola surveillance. *Nature*, *530*(7589), 228-232.
31. Rahimzadeh, V. (2024). US regulation of medical artificial intelligence and machine learning (AI/ML) research and development. *Research Handbook on Health, AI and the Law*, 273-290.
32. Rhoads, D. D., Pournaras, S., Leber, A., Balada-Llasat, J. M., Harrington, A., Sambri, V., ... & Lu, D. Y. (2023). Multicenter evaluation of the BIOFIRE blood culture identification 2 panel for detection of bacteria, yeasts, and antimicrobial resistance genes in positive blood culture samples. *Journal of Clinical Microbiology*, *61*(6), e01891-22.
33. Shadmi, E., Chen, Y., Dourado, I., Faran-Perach, I., Furler, J., Hangoma, P., ... & Willems, S. (2020). Health equity and COVID-19: global perspectives. *International journal for equity in health*, *19*(1), 104.
34. Simner, P. J., Miller, S., & Carroll, K. C. (2018). Understanding the promises and hurdles of metagenomic next-generation sequencing as a diagnostic tool for infectious diseases. *Clinical Infectious Diseases*, *66*(5), 778-788.
35. Spencer, M. D., Winglee, K., Passaretti, C., Earl, A. M., Manson, A. L., Mulder, H. P., ... & Fodor, A. A. (2019). Whole genome sequencing detects inter-facility transmission of carbapenem-resistant Klebsiella pneumoniae. *Journal of Infection*, *78*(3), 187-199.

36. Tegally, H., Wilkinson, E., Giovanetti, M., Iranzadeh, A., Fonseca, V., Giandhari, J., ... & De Oliveira, T. (2021). Detection of a SARS-CoV-2 variant of concern in South Africa. *Nature*, *592*(7854), 438-443.
37. Vashisht, V., Vashisht, A., Mondal, A. K., Farmaha, J., Alptekin, A., Singh, H., ... & Kolhe, R. (2023). Genomics for emerging pathogen identification and monitoring: prospects and obstacles. *BioMedInformatics*, *3*(4), 1145-1177.
38. Walker, T. M., Kohl, T. A., Omar, S. V., Hedge, J., Elias, C. D. O., Bradley, P., ... & Peto, T. E. (2015). Whole-genome sequencing for prediction of Mycobacterium tuberculosis drug susceptibility and resistance: a retrospective cohort study. *The Lancet infectious diseases*, *15*(10), 1193-1202.
39. Wang, H., Zhang, Y., Zhou, J., Li, M., Chen, Y., Liu, Y., ... & Wang, A. (2022). Rapid visual detection of hepatitis C virus using reverse transcription recombinase-aided amplification–Lateral flow dipstick. *Frontiers in Cellular and Infection Microbiology*, *12*, 816238.
40. Wilson, M. R., Sample, H. A., Zorn, K. C., Arevalo, S., Yu, G., Neuhaus, J., ... & Chiu, C. Y. (2019). Clinical metagenomic sequencing for diagnosis of meningitis and encephalitis. *New England Journal of Medicine*, *380*(24), 2327-2340.
41. Wu, X., Li, R., Lai, T., Tao, G., Liu, F., & Li, N. (2021). Universal nanoparticle counting platform for tetraplexed biomarkers by integrating immunorecognition and nucleic acid hybridization in one assay. *Analytical chemistry*, *93*(50), 16873-16879.
42. Yang, Y., Yang, X., Tan, Y., & Yuan, Q. (2023). Wearable microneedle array-based CRISPR sensor for continuous monitoring of interstitial fluid nucleic acids. *Nature Biomedical Engineering*, *7*(11), 1465-1476.
43. Yasir, M., Karim, A. M., Malik, S. K., Bajaffer, A. A., & Azhar, E. I. (2022). Prediction of antimicrobial minimal inhibitory concentrations for Neisseria gonorrhoeae using machine learning models. *Saudi Journal of Biological Sciences*, *29*(5), 3687-3693.
44. Zhang, A., Teng, L., & Alterovitz, G. (2021). An explainable machine learning platform for pyrazinamide resistance prediction and genetic feature identification of Mycobacterium tuberculosis. *Journal of the American Medical Informatics Association*, *28*(3), 533-540.
45. Zhou, S., Lou, E. G., Schedler, J., Ensor, K. B., Hopkins, L., & Stadler, L. B. (2024). Comparative analysis of culture-and ddPCR-based wastewater surveillance for carbapenem-resistant bacteria. *Environmental Science: Water Research & Technology*, *11*(1), 51-63.